Inflammatory bowel disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Inflammatory bowel disease patients with an active form of ulcerative colitis with a moderate exacerbation of their disease and in whom the inflammation does not go beyond the flexure lienalis 2. Irritable bowel syndrome control patients with endoscopically proven absence of inflammation and adenomas 3. Participants of any age (above 18 years) and either sex are included
Exclusion criteria
Exclusion criteria: 1. Inflammatory bowel disease patients with severe inflammation, including Crohn's disease and pancolitis 2. Irritable bowel syndrome control patients with medical complaints and/or use of anti-inflammatory medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Whole genome gene expression modifications by microarray analysis (4x44K Agilent platform) 2. Apparent total nitroso compounds in faecal matter by thermal energy analysis 3. Faecal water genotoxicity (30 minute exposure to 10% faecal water) by comet assay analysis in the adenocarcinoma cell line Caco-2 All outcomes are measured at baseline and post intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Calprotectin levels in faecal matter as a measure of inflammation 2. Analysis of food frequency questionnaires recorded during intervention period 3. Possible determination of N-nitroso compound levels by thermal energy analysis in urine and blood All outcomes are measured at baseline and post intervention. | — |
Countries
Netherlands